JP5710623B2 - 自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法 - Google Patents
自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法 Download PDFInfo
- Publication number
- JP5710623B2 JP5710623B2 JP2012532147A JP2012532147A JP5710623B2 JP 5710623 B2 JP5710623 B2 JP 5710623B2 JP 2012532147 A JP2012532147 A JP 2012532147A JP 2012532147 A JP2012532147 A JP 2012532147A JP 5710623 B2 JP5710623 B2 JP 5710623B2
- Authority
- JP
- Japan
- Prior art keywords
- pbc
- elisa
- serum
- autoantigen
- assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 title claims description 205
- 208000033222 Biliary cirrhosis primary Diseases 0.000 title claims description 205
- 208000012654 Primary biliary cholangitis Diseases 0.000 title claims description 205
- 238000000034 method Methods 0.000 title claims description 70
- 210000002966 serum Anatomy 0.000 claims description 124
- 101710198391 Hexokinase-1 Proteins 0.000 claims description 84
- 102100030338 Hexokinase-1 Human genes 0.000 claims description 84
- 239000000427 antigen Substances 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 45
- 230000027455 binding Effects 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 description 156
- 238000003556 assay Methods 0.000 description 77
- 238000001514 detection method Methods 0.000 description 68
- 238000002493 microarray Methods 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 43
- 239000000523 sample Substances 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 41
- 229940030980 inova Drugs 0.000 description 33
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 30
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 238000012286 ELISA Assay Methods 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 22
- 208000023275 Autoimmune disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 206010009944 Colon cancer Diseases 0.000 description 20
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 238000003018 immunoassay Methods 0.000 description 19
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 18
- 230000035945 sensitivity Effects 0.000 description 18
- 238000004364 calculation method Methods 0.000 description 17
- 230000009977 dual effect Effects 0.000 description 17
- 238000012790 confirmation Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 101001083183 Homo sapiens Hexokinase-1 Proteins 0.000 description 12
- 108700026244 Open Reading Frames Proteins 0.000 description 12
- 102000053845 human HK1 Human genes 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 108010026552 Proteome Proteins 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000007790 solid phase Substances 0.000 description 9
- 239000000020 Nitrocellulose Substances 0.000 description 8
- 239000004793 Polystyrene Substances 0.000 description 8
- 208000021386 Sjogren Syndrome Diseases 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 238000010606 normalization Methods 0.000 description 8
- 229920002223 polystyrene Polymers 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 101001091328 Homo sapiens Kelch-like protein 12 Proteins 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000058108 human KLHL12 Human genes 0.000 description 7
- 238000010208 microarray analysis Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 6
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 6
- 102100026375 Protein PML Human genes 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000002529 anti-mitochondrial effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 6
- 229960001661 ursodiol Drugs 0.000 description 6
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 5
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 230000003460 anti-nuclear Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000000633 nuclear envelope Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241000219061 Rheum Species 0.000 description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000002820 assay format Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000010079 rubber tapping Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 102100036361 Calcium-binding and coiled-coil domain-containing protein 2 Human genes 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 206010057573 Chronic hepatic failure Diseases 0.000 description 3
- 208000010334 End Stage Liver Disease Diseases 0.000 description 3
- 101000714579 Homo sapiens Calcium-binding and coiled-coil domain-containing protein 2 Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 201000011152 Pemphigus Diseases 0.000 description 3
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 3
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000003622 anti-hsv Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 208000011444 chronic liver failure Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 2
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 102100029242 Hexokinase-2 Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- 101000914251 Homo sapiens Major centromere autoantigen B Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102100025833 Major centromere autoantigen B Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 241000953555 Theama Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 108050000749 BTB/POZ domains Proteins 0.000 description 1
- 241000984553 Banana streak virus Species 0.000 description 1
- 208000017283 Bile Duct disease Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100029274 Hexokinase HKDC1 Human genes 0.000 description 1
- 101710198385 Hexokinase-2 Proteins 0.000 description 1
- 102100029236 Hexokinase-3 Human genes 0.000 description 1
- 101710198398 Hexokinase-3 Proteins 0.000 description 1
- 102100029237 Hexokinase-4 Human genes 0.000 description 1
- 101000988521 Homo sapiens Hexokinase HKDC1 Proteins 0.000 description 1
- 101000840558 Homo sapiens Hexokinase-4 Proteins 0.000 description 1
- 101001050577 Homo sapiens Kinesin-like protein KIF2A Proteins 0.000 description 1
- 101000701614 Homo sapiens Nuclear autoantigen Sp-100 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 108010037522 Promyelocytic Leukemia Protein Proteins 0.000 description 1
- 102000006802 Retinoic Acid Receptor alpha Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 238000011869 Shapiro-Wilk test Methods 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003476 anti-centromere Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 102000044266 human Sp100 Human genes 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 208000012318 pareses Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000013579 wash concentrate Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24876809P | 2009-10-05 | 2009-10-05 | |
| US61/248,768 | 2009-10-05 | ||
| PCT/US2010/051475 WO2011044125A1 (en) | 2009-10-05 | 2010-10-05 | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015041977A Division JP6012794B2 (ja) | 2009-10-05 | 2015-03-04 | 自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506837A JP2013506837A (ja) | 2013-02-28 |
| JP2013506837A5 JP2013506837A5 (US07794700-20100914-C00194.png) | 2013-10-17 |
| JP5710623B2 true JP5710623B2 (ja) | 2015-04-30 |
Family
ID=43857083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532147A Active JP5710623B2 (ja) | 2009-10-05 | 2010-10-05 | 自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法 |
| JP2015041977A Active JP6012794B2 (ja) | 2009-10-05 | 2015-03-04 | 自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015041977A Active JP6012794B2 (ja) | 2009-10-05 | 2015-03-04 | 自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法 |
Country Status (7)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011044125A1 (en) * | 2009-10-05 | 2011-04-14 | Ambergen, Inc. | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens |
| CN102627695B (zh) * | 2012-03-23 | 2014-10-22 | 中国医学科学院北京协和医院 | 原发性胆汁性肝硬化特异性自身抗原及其应用 |
| CN104292323B (zh) * | 2012-03-23 | 2017-04-05 | 中国医学科学院北京协和医院 | 原发性胆汁性肝硬化特异性自身抗原及其应用 |
| CN104292322A (zh) * | 2012-03-23 | 2015-01-21 | 中国医学科学院北京协和医院 | 原发性胆汁性肝硬化特异性自身抗原及其应用 |
| EP3938787A4 (en) * | 2019-03-15 | 2022-12-28 | Chan Zuckerberg Biohub, Inc. | SELF-ANTIBODY USED AS A BIOMARKER FOR PARANEOPLASTIC ENCEPHALITIS ASSOCIATED WITH TESTICULAR CANCER |
| AU2022206267A1 (en) * | 2021-01-08 | 2023-01-19 | Inova Diagnostics, Inc. | Compositions and methods for diagnosing primary biliary cirrhosis |
| CN113009148A (zh) * | 2021-02-10 | 2021-06-22 | 中国医学科学院北京协和医院 | 用于诊断抗sp100抗体阳性与阴性pbc患者的糖链标志物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| ZA879403B (en) * | 1986-12-16 | 1988-06-23 | Amrad Corp Ltd | Primary biliary cirrhosis autoantigen |
| JPH03291568A (ja) * | 1990-04-09 | 1991-12-20 | Igaku Seibutsugaku Kenkyusho:Kk | 抗ミトコンドリアｍ↓２抗体の検出用試薬及び測定法 |
| JP3472048B2 (ja) * | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
| WO1997049720A1 (en) * | 1996-06-24 | 1997-12-31 | Eric Gershwin | Recombinant fusion protein comprising pdc-e2, bcoadc-e2, and ogdc-e2 and uses thereof |
| JPH1138008A (ja) * | 1997-07-16 | 1999-02-12 | Sumitomo Electric Ind Ltd | 自己抗体の検出方法および検出試薬 |
| WO2002008383A2 (en) * | 2000-07-24 | 2002-01-31 | The General Hospital Corporation | Sp110, a polypeptide component of the nuclear body |
| US20040221327A1 (en) * | 2001-03-27 | 2004-11-04 | Gershwin M. Eric | Antibodies against autoantigens of primary billary cirrhosis and methods of making and using them |
| US20070281911A1 (en) * | 2004-01-21 | 2007-12-06 | Gilead Sciences Inc. | Use of Adefovir or Tenofovir for Inhibiting Mmtv-Like Viruses Involved in Breast Cancer and Primary Biliary Cirrhosis |
| JP2006071409A (ja) * | 2004-09-01 | 2006-03-16 | Kansai Tlo Kk | シェーグレン症候群診断キット |
| WO2007043103A1 (ja) * | 2005-09-30 | 2007-04-19 | Kansai Technology Licensing Organization Co., Ltd. | シェーグレン症候群診断法及び診断キット |
| JP2007245505A (ja) | 2006-03-15 | 2007-09-27 | Fujifilm Corp | 平版印刷版原版、平版印刷版およびその作製方法 |
| US20090047689A1 (en) * | 2007-06-20 | 2009-02-19 | John Kolman | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma |
| JP5471724B2 (ja) | 2009-09-30 | 2014-04-16 | 大日本印刷株式会社 | 化粧シート |
| WO2011044125A1 (en) * | 2009-10-05 | 2011-04-14 | Ambergen, Inc. | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens |
| JP2012206482A (ja) | 2011-03-30 | 2012-10-25 | Daikyonishikawa Corp | 樹脂成形品の組付け構造 |
-
2010
- 2010-10-05 WO PCT/US2010/051475 patent/WO2011044125A1/en active Application Filing
- 2010-10-05 EP EP10822527.7A patent/EP2486407B1/en active Active
- 2010-10-05 ES ES15194007.9T patent/ES2681839T3/es active Active
- 2010-10-05 ES ES10822527.7T patent/ES2566762T3/es active Active
- 2010-10-05 JP JP2012532147A patent/JP5710623B2/ja active Active
- 2010-10-05 AU AU2010303628A patent/AU2010303628B2/en active Active
- 2010-10-05 EP EP15194007.9A patent/EP3012631B1/en active Active
- 2010-10-05 CA CA2965189A patent/CA2965189C/en active Active
- 2010-10-05 CA CA2776688A patent/CA2776688C/en active Active
- 2010-10-05 US US13/500,411 patent/US8852956B2/en active Active
-
2014
- 2014-06-27 US US14/318,498 patent/US20150057170A1/en not_active Abandoned
-
2015
- 2015-03-04 JP JP2015041977A patent/JP6012794B2/ja active Active
- 2015-10-07 AU AU2015238816A patent/AU2015238816B2/en active Active
-
2017
- 2017-03-24 US US15/469,350 patent/US11885802B2/en active Active
-
2023
- 2023-11-28 US US18/522,114 patent/US20240159749A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2776688C (en) | 2017-06-20 |
| AU2010303628B2 (en) | 2015-07-09 |
| AU2015238816B2 (en) | 2017-10-05 |
| ES2566762T3 (es) | 2016-04-15 |
| EP3012631B1 (en) | 2018-05-23 |
| US20240159749A1 (en) | 2024-05-16 |
| EP3012631A1 (en) | 2016-04-27 |
| JP2013506837A (ja) | 2013-02-28 |
| EP2486407A1 (en) | 2012-08-15 |
| EP2486407A4 (en) | 2013-04-10 |
| WO2011044125A1 (en) | 2011-04-14 |
| US20150057170A1 (en) | 2015-02-26 |
| US20120244562A1 (en) | 2012-09-27 |
| CA2776688A1 (en) | 2011-04-14 |
| WO2011044125A8 (en) | 2012-09-13 |
| ES2681839T3 (es) | 2018-09-17 |
| EP2486407B1 (en) | 2016-02-10 |
| US8852956B2 (en) | 2014-10-07 |
| CA2965189A1 (en) | 2011-04-14 |
| AU2015238816A1 (en) | 2015-10-29 |
| AU2010303628A1 (en) | 2012-04-12 |
| JP6012794B2 (ja) | 2016-10-25 |
| US11885802B2 (en) | 2024-01-30 |
| CA2965189C (en) | 2020-06-30 |
| JP2015143695A (ja) | 2015-08-06 |
| US20170307607A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6012794B2 (ja) | 自己抗原を使用する原発性胆汁性肝硬変（ｐｂｃ）を診断するための方法 | |
| US11199549B2 (en) | MEl'hods and means for diagnosing spondylarthritis using autoantibody markers | |
| Behnert et al. | An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor | |
| Simon et al. | Detection of anti-pentraxin-3 autoantibodies in ANCA-associated vasculitis | |
| Heinlen et al. | Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides | |
| US11609237B2 (en) | Marker sequences for diagnosing and stratifying systemic sclerosis patients | |
| US20180059107A1 (en) | Method of detecting or diagnosing sjogren's syndrome based on the presence of auto-antibody against aquaporin 5 | |
| US11719694B2 (en) | Biomarkers in autoimmune liver disease | |
| EP2482074A1 (en) | Methods and means for diagnosing vasculitis | |
| WO2019081692A1 (en) | METHOD AND MEANS FOR DIAGNOSING AUTOIMMUNE HEPATITIS USING SELF-ANTIBODY MARKERS | |
| WO2021138273A2 (en) | Autoantibodies as biomarkers for autoimmune polyglandular syndrome type 1 | |
| WO2022176958A1 (ja) | リンパ球性下垂体前葉炎及びその類縁疾患のマーカー並びにその利用 | |
| JP5605375B2 (ja) | Ｋｕ８６に対する自己抗体の免疫測定方法、それに用いるキット、及びそれを用いた原発性肝細胞癌の判定方法 | |
| US20170199187A1 (en) | Compositions and methods for the diagnosis of systemic autoimmune disease | |
| WO2020035123A1 (en) | Autoantibodies binding to negative elongation factor e (nelf-e) for diagnosing sarcoidosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130829 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130829 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140410 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140707 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140714 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140808 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140815 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140820 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140903 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150304 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5710623 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |